Frédéric Rolland - Researcher Profile

Publications

2 shown

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,190
Institution: Institut Génétique Nantes Atlantique

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-6957-0894

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.